How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Sell
29
NBY Quote, Financials, Valuation and Earnings
Last price:
$0.59
Seasonality move
:
-10.86%
Day range:
$0.57 - $0.61
52-week range:
$0.36 - $9.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.16x
P/B ratio:
2.25x
Volume:
22.1K
Avg. volume:
56.5K
1-year change:
-79.19%
Market cap:
$3.5M
Revenue:
$9.8M
EPS (TTM):
-$35.80
Analysts' Opinion
-
Consensus RatingNovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $0.85, NovaBay Pharmaceuticals has an estimated upside of 41.64% from its current price of $0.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.85 representing 100% downside risk from its current price of $0.60.
Fair Value
-
According to the consensus of 1 analyst, NovaBay Pharmaceuticals has 41.64% upside to fair value with a price target of $0.85 per share.
NBY vs. S&P 500
-
Over the past 5 trading days, NovaBay Pharmaceuticals has overperformed the S&P 500 by 15.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
NovaBay Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NovaBay Pharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter NovaBay Pharmaceuticals reported revenues of $2.4M.
Earnings Growth
-
NovaBay Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter NovaBay Pharmaceuticals reported earnings per share of -$0.60.
Enterprise value:
3.6M
EV / Invested capital:
--
Price / LTM sales:
0.16x
EV / EBIT:
--
EV / Revenue:
0.37x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.9M
Return On Assets:
-144.37%
Net Income Margin (TTM):
-73.09%
Return On Equity:
-461.38%
Return On Invested Capital:
-334.47%
Operating Margin:
-43.47%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $14.4M | $10.5M | $9.8M | $2.1M | $2.3M | |
| Gross Profit | $7.8M | $6.1M | $6.5M | $1.1M | $1.5M | |
| Operating Income | -$7.7M | -$4.1M | -$5M | -$1M | -$1.3M | |
| EBITDA | -$7.2M | -$4.1M | -$5.9M | -$1.1M | -$1.2M | |
| Diluted EPS | -$346.50 | -$115.87 | -$7.47 | -$28.58 | -$0.25 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.2M | $13.2M | $11.3M | $7.2M | $1.9M | |
| Total Assets | $15.2M | $24M | $16.4M | $9M | $3.4M | |
| Current Liabilities | $2.8M | $3.4M | $4.3M | $4.3M | $2.8M | |
| Total Liabilities | $2.9M | $13.8M | $5.8M | $5.7M | $3.6M | |
| Total Equity | $12.3M | $10.2M | $10.6M | $3.3M | -$129K | |
| Total Debt | -- | $105K | -- | $1.1M | $565K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.7M | -$4.3M | -$5.2M | -$722K | -$972K | |
| Cash From Investing | -$112K | -$19K | $1.1M | -$3K | -- | |
| Cash From Financing | $4.6M | $1.9M | $1.5M | -$26K | $500K | |
| Free Cash Flow | -$6.8M | -$4.3M | -$5.2M | -$725K | -$972K | |
NBY
Sector
Market Cap
$3.5M
$34.2M
Price % of 52-Week High
6.61%
42.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-79.19%
-41.76%
Beta (5-Year)
0.897
0.737
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.56
200-day SMA
Sell
Level
$0.75
Bollinger Bands (100)
Sell
Level
0.56 - 0.68
Chaikin Money Flow
Sell
Level
-397.9M
20-day SMA
Buy
Level
$0.57
Relative Strength Index (RSI14)
Buy
Level
55.05
ADX Line
Sell
Level
19.18
Williams %R
Sell
Level
-9.6129
50-day SMA
Sell
Level
$0.61
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
690.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-78.0768)
Sell
CA Score
(Annual)
Level (-5.5337)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (13.1478)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Stock Forecast FAQ
In the current month, NBY has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NBY average analyst price target in the past 3 months is $0.85.
-
Where Will NovaBay Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that NovaBay Pharmaceuticals share price will rise to $0.85 per share over the next 12 months.
-
What Do Analysts Say About NovaBay Pharmaceuticals?
Analysts are divided on their view about NovaBay Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NovaBay Pharmaceuticals is a Sell and believe this share price will drop from its current level to $0.85.
-
What Is NovaBay Pharmaceuticals's Price Target?
The price target for NovaBay Pharmaceuticals over the next 1-year time period is forecast to be $0.85 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NBY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NovaBay Pharmaceuticals is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of NBY?
You can purchase shares of NovaBay Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NovaBay Pharmaceuticals shares.
-
What Is The NovaBay Pharmaceuticals Share Price Today?
NovaBay Pharmaceuticals was last trading at $0.59 per share. This represents the most recent stock quote for NovaBay Pharmaceuticals. Yesterday, NovaBay Pharmaceuticals closed at $0.60 per share.
-
How To Buy NovaBay Pharmaceuticals Stock Online?
In order to purchase NovaBay Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Rocket Lab Vs Intuitive Machines Stock
The commercialization of outer space is now in full swing,…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
40
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 33x
Alerts
Buy
58
AGX alert for Apr 22
Argan [AGX] is up 3.08% over the past day.
Sell
44
INOD alert for Apr 22
Innodata [INOD] is up 5.26% over the past day.
Sell
44
UHS alert for Apr 22
Universal Health Services [UHS] is up 2.73% over the past day.
